Surrozen, Inc./DE

Surrozen, Inc.

Biotechnology • Healthcare • South San Francisco, CA, United States • SRZNW (NCM)

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

650 489 9000 171 Oyster Point Boulevard, South San Francisco, CA 94080, United States

Stock Performance (90 Days)

Data through Dec 22, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Insider Stock Purchases: December 03, 2025 - Quiver Quantitative
Quiver Quantitative • Dec 3
Wnt Pathway Therapeutics Pioneer Surrozen to Showcase Pipeline at Major Healthcare Conference Sept 10 - Stock Titan
Stock Titan • Sep 3
US Stock Market top gainers and losers on November 4: Surrozen, Inc sees 220% jump, Tradr 2X Long SRPT Dai - The Economic Times
The Economic Times • Nov 5
Surrozen (NASDAQ: SRZN) grants inducement options at $12.94 to new CFO, 50,000 shares - Stock Titan
Stock Titan • Nov 12
Insider Stock Purchases: November 18, 2025 - Quiver Quantitative
Quiver Quantitative • Nov 18

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Surrozen, Inc./DE had layoffs?
No layoff events have been recorded for Surrozen, Inc./DE in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Surrozen, Inc./DE have?
Surrozen, Inc./DE has approximately 40 employees.
What industry is Surrozen, Inc./DE in?
Surrozen, Inc./DE operates in the Biotechnology industry, within the Healthcare sector.
Is Surrozen, Inc./DE a publicly traded company?
Yes, Surrozen, Inc./DE is publicly traded under the ticker symbol SRZNW on the NCM.
Where is Surrozen, Inc./DE headquartered?
Surrozen, Inc./DE is headquartered in South San Francisco, CA, United States at 171 Oyster Point Boulevard, South San Francisco, CA 94080, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.